SANTA CLARA, Calif.--(BUSINESS WIRE)--
Affymetrix, Inc. (NASDAQ:AFFX - News) today announced that its GeneChip® System 3000Dx v.2 (GCS 3000Dx v.2) has been approved by China's State Food and Drug Administration (SFDA) for in vitro diagnostic use. The GCS 3000Dx v.2 is the first microarray instrument system to be granted SFDA registration for array-based diagnostics for enabling personalized medicine. China has more than 2,000 clinical centers that will now have access to the only SFDA-cleared microarray platform for clinical testing.
The molecular diagnostic market in China is the fastest growing in the world and represents a significant growth opportunity for Affymetrix in Asia. “We are delighted to be the first SFDA-cleared microarray platform, as this will enable us to expand into the clinical diagnostics applications,” says Chris Barbazette, Vice President, Commercial Operations International Markets at Affymetrix.
The GCS 3000Dx v.2 microarray platform has a proven record of successful development and commercialization through partnership via the Powered by Affymetrix™ (PbA) program. A number of companies are developing molecular diagnostic tests in cancer, cardiovascular diseases, and inherited disorders based on the Affymetrix GeneChip platform. More than ten tests are in the pipeline for regulatory clearance. Two FDA-cleared tests (Roche AmpliChip® CYP450 Test and Pathwork® Diagnostics' Tissue of Origin Test) and three CE-IVD marked tests, including Skyline Diagnostic’s AML test, are currently on the market. These tests and Affymetrix’ own solutions for cytogenetics, cancer, and pharmacogenomics are part of an increasing menu of clinical applications that can be run on the SFDA-cleared GeneChip System.
“Having an SFDA-cleared system and a wide-range of clinical tests will enable physicians in China to bring personalized medicine to their patients faster,” says Dr. Ming Zhang at Hangzhou Bio-San Biochemical Technologies Company.
“This registration clearance is a significant accomplishment for Affymetrix and supports our global clinical strategy. It connects us more closely to physicians in China wanting to utilize clinically relevant genomic biomarkers that improve their patients’ health and wellness,” said Andy Last, Executive Vice President of Genetic Analysis and Clinical Applications Business Unit at Affymetrix.
The GCS 3000Dx v.2 microarray System is cleared for in vitro diagnostic use in the United States, Japan, CE-IVD marked in Europe, and is also available in Canada, Singapore, Australia, India, and Saudi Arabia.
In addition to the GCS 3000Dx v.2, Affymetrix also offers a Clinical Toolkit, which contains the US FDA-cleared and CE-IVD marked Gene Profiling Reagents and the Gene Profiling Array cGMP U133 P2, the cGMP-manufactured version of the widely cited GeneChip® Human Genome U133 Plus 2.0 Array. The Affymetrix® Clinical Toolkit provides a proven path to market, enabling test developers to save time and money while reducing regulatory risks.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies as well as leading academic, government, and nonprofit research institutes. About 2,200 systems have been shipped around the world, and more than 25,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, CA, and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risk relating to the Company’s ability to successfully commercialize new products, risk relating to past and future acquisitions, including the ability of the Company to successfully integrate such acquisitions into its existing business; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, risks associated with manufacturing and product development; personnel retention; uncertainties relating to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Annual Report on Form 10-K for the year ended December 31, 2010, and other SEC reports. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the property of Affymetrix, Inc.
Excerpt from:
China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine
- Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer [Last Updated On: August 17th, 2024] [Originally Added On: May 3rd, 2010]
- A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs [Last Updated On: August 17th, 2024] [Originally Added On: August 2nd, 2010]
- Pharmacogenomics [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Drug Firms Want More Access to Genetic Specimens - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- India joins genome club -Genomics in India - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Classic: Weinshilboum: Inherited Variations in Drug and Neurotransmitter Metabolism 1981 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict... - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Antidepressant Use Increases Significantly - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]
- Kelan G. Tantisira, MD, MPH - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 31st, 2011]
- Human Security Thesis, personalized medicine, pharmacogenomics, Pharmacogenomics - Introduction - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pamela Sklar: 2011 Allen Institute for Brain Science Symposium - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pharmacy Doctor Oct 2011 A #1.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- R. Stephanie Huang, PhD: The Role of Pharmacogenomics and Anticancer Drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 19th, 2011]
- Individualized Molecular Testing for Personalized Medicine - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 21st, 2011]
- Where Science Meets Faith: Anticipating the Future - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Pharmacogenomics of psychotropic drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 6th, 2011]
- 2008 IPIT Awards Seminar: Hans Hogerzeil - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 7th, 2011]
- Asuragen CLIA Pharmacogenomic Services - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 8th, 2011]
- Pilot Demonstration Projects Group 4: Pharmacogenomics - Alan Shuldiner - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 16th, 2011]
- Pharmacogenomics - Howard McLeod - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 17th, 2011]
- Clinical Implementation of Psychiatric Pharmacogenomics - David Mrazek - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 10th, 2012]
- PROMISE - Bionexus Partnership Launching montage - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Dr. William Figg: Handling Pharmacogenomic Information - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 19th, 2012]
- Using Payer Data to Analyze Impact of Pharmacogenomic Approaches - Robert Epstein - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 22nd, 2012]
- Dr. Russ Altman on Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 26th, 2012]
- AssureRx Health Secures $8M Financing with Silicon Valley Bank to Support Growth [Last Updated On: August 17th, 2024] [Originally Added On: January 31st, 2012]
- BSc Biomedical Sciences courses at Brunel University - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 1st, 2012]
- Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015 [Last Updated On: August 17th, 2024] [Originally Added On: February 3rd, 2012]
- Gaming Wins Big at National Science Foundation's Visualization Challenge [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2012]
- SBCE to organise international meet on Molecular Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Future US Nucleic Acid Testing Market Outlook [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- ACLA Says Cuts in Medicare Lab Payments Could Hurt Nascent Personalized Dx Segment [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2012]
- OncTerm- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 21st, 2012]
- A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2012]
- International meet on molecular medicine begins at SBCE [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Darien High Schoolers fare well at science fair [Last Updated On: August 17th, 2024] [Originally Added On: February 27th, 2012]
- US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- ACM Global Central Lab Launches Workshop Series to Share Expert Insights on Navigating Global Clinical Trials with a ... [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Fitch: Drug Makers Continue to Face Challenges at the Beginning of the Drug Channel [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx? [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Generex to Meet with FDA about AE37 HER2 Peptide Vaccine; Companion Dx Path Still Unclear [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2012]
- Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic Reports Fiscal Year 2011 Financial Results [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic's Q4 Revenues Increase 69 Percent [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ... [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- USPSTF Updating BRCA Testing Recommendations for Asymptomatic Women; Accepting Public Input [Last Updated On: August 17th, 2024] [Originally Added On: March 8th, 2012]
- Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc. [Last Updated On: August 17th, 2024] [Originally Added On: March 10th, 2012]
- WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST [Last Updated On: August 17th, 2024] [Originally Added On: March 13th, 2012]
- Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ... [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- WSU recruits geneticists in new research venture [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Free Book Download - Psychiatric Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 16th, 2012]
- PanGenX Takes Semantic-based Approach to Data Integration, Analytics for Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2012]
- Research and Markets: Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- Quest Launches MDx that May Predict Kidney Transplant Rejection Earlier than Current Methods [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- EMERGE Network Launches Publicly Available Database of Phenotype Identification Algorithms [Last Updated On: August 17th, 2024] [Originally Added On: March 23rd, 2012]
- Prospective Outcomes Trial Shows Agendia's MammaPrint Safely Reduces Chemo Use in Low-Risk Patients [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis [Last Updated On: August 17th, 2024] [Originally Added On: March 28th, 2012]
- St. Jude's Evans Receives Pharmacists Assn. Award [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Perkins Chain Hires New CEO [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- PGx Highlights from American College of Cardiology Annual Meeting [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Collecting Cancer Data [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- UNC Analysis Finds Beta1-AR Alleles Impact Survival in Patients Treated with Beta-Blockers [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Q&A: GE Healthcare's Mark Dente on the Challenges of Integrating Genomics Data with EMRs [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- Eastday-Neurosurgeon, geneticist take top prizes in science [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- A New 'Omics Emerges [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- Up to the Task [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- NHGRI Plans to Fund More Clinical Sequencing Projects [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2012]
- Doctor’s role is key to cancer fight [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2012]
- People in the News: Josh LaBaer in as New President of US HUPO and More [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Convey, CLC Bio to Provide Combined Software, Hardware NGS Data-Analysis Solution [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Downloads & Upgrades: Roche's 454 Software, Omixon Simulation Service, OmicsOffice, and Others [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]